News archive

Latest news

24 Oct 2023

Idorsia announces financial results for the first nine months of 2023 – adapting the company to create sustainable value

06 Sep 2023

Idorsia reacquires the world-wide rights to aprocitentan

25 Jul 2023

Idorsia announces financial results for the first half 2023 – adapting the company to create sustainable value

21 Jul 2023

Idorsia announces a cost reduction initiative to be implemented by the end of 2023

20 Jul 2023

Idorsia sells its Asia Pacific (ex-China) operations – including select license rights to products – to Sosei Heptares for a total consideration of CHF 400 million

10 Jul 2023

Idorsia announces its insomnia medication, QUVIVIQ (daridorexant), is now covered by CVS

20 Jun 2023

Idorsia has secured bridge financing in the amount of CHF 75 million

06 Jun 2023

Idorsia has entered into exclusive negotiations with regard to a prospective strategic transaction for its Asia Pacific (ex-China) operations for up to CHF 400 million

30 May 2023

Idorsia announces a change to commercial leadership

25 Apr 2023

Idorsia announces financial results for the first quarter 2023 – QUVIVIQ now the leading branded insomnia medicine in the commercial market in the US

07 Feb 2023

Idorsia announces financial results for 2022 – building momentum to become a leading mid-sized biopharmaceutical company

06 Feb 2023

Idorsia announces the results of REACT a Phase 3 study of clazosentan in patients following aneurysmal subarachnoid hemorrhage

09 Jan 2023

Idorsia presents at the 41st J.P. Morgan Healthcare Conference – Achievements in 2022 provide the foundation for our success in 2023

16 Nov 2022

Idorsia and Simcere enter into a licensing agreement for daridorexant in China

25 Oct 2022

Idorsia announces financial results for the first nine months of 2022 – QUVIVIQ becoming a global brand

03 Oct 2022

Idorsia Japan announces positive results with daridorexant in a Phase 3 study of Japanese patients with insomnia

27 Sep 2022

Idorsia secures additional cash by entering into a building sale and leaseback agreement

26 Jul 2022

Idorsia announces financial results for the first half 2022 – reaching commercial stage

23 May 2022

Positive Phase 3 study with aprocitentan demonstrates significant antihypertensive efficacy in patients with resistant hypertension

26 Apr 2022

Idorsia announces financial results for the first quarter 2022 – first product launched, second in the starting blocks

Ad hoc announcements pursuant to Art. 53 LR

Ad hoc announcements pursuant to Art. 53 LR have been classified from 2021 onwards. A full archive of press releases can be found under the "All" tab.

News in German

As a biopharmaceutical company headquartered in Allschwil/Basel, Switzerland, we have many people interested in reading more about the company in German.

Read selected news in German